Cross-Sectional Survey of Rheumatologists and Dermatologists to Assess the Effectiveness of the Baricitinib Additional Risk Minimization Measures in Canada First published 14/01/2025 Last updated 13/02/2025 EU PAS number:EUPAS1000000438 Study Planned